The biotech sector is one of my favorite sectors since it is not only constantly growing and with companies that are always doing wonderful research, products, and solutions, but it is also a sector that is constantly innovating and contributing to the health of the human being. If you want to participate as an investor in this sector and take advantage of companies that have great growth opportunities, here are three biotech stocks with potential that you can consider adding to your portfolio.Nkarta (NKTX) ...

Amphastar Pharmaceuticals (AMPH) closed at $54.94 in the latest trading session, marking a -0.81% move from the prior day. The stock's performance was behind the S&P 500's daily loss of 0.06%. At the same time, the Dow added 0.35%, and the tech-heavy Nasdaq lost 0.76%.Shares of the specialty pharmaceutical company witnessed a loss of 10.45% over the previous month, trailing the performance of the Medical sector with its gain of 1.65% and the S&P 500's gain of 3.36%.Analysts and investors alike will be keepi ...

The U.S. economy showed robustness in 2023 while expanding at a healthy pace in the final three months and squashing recession fearmongering. The domestic economy displayed astounding resilience in the face of the Federal Reserve’s monetary tightening campaign to tame relentless price pressures. It continued to thrive, banking on the uptick in consumer outlays and strength in the labor market.The U.S. economy accelerated at an annualized rate of 3.3% in the final quarter of 2023, more than economists’ forec ...

Toward the end of 2023, the economy started showing signs of stabilization and easing inflationary pressure as the Fed finally decided to keep interest rates unchanged. This is likely to benefit generic drugmakers like Amphastar Pharmaceuticals (AMPH) , Teva Pharmaceutical (TEVA) and Dr. Reddy’s Laboratories (RDY) , who can potentially benefit from declining costs in the long run.These drugmakers are also focusing on new product launches or existing products with high gross margins to support their top and ...

Investors seeking healthy returns should add stocks with favorable liquidity to their portfolios.Liquidity measures a company’s capability to meet its short-term debt obligations. Stocks with high liquidity levels have always been in demand, owing to their potential to provide maximum returns.Investors should be alert before considering such stocks. While a high liquidity level may imply that the company is clearing its dues faster than its peers, it may also suggest that it cannot utilize assets competentl ...

The most recent trading session ended with Amphastar Pharmaceuticals (AMPH) standing at $54.03, reflecting a -1.44% shift from the previouse trading day's closing. This change lagged the S&P 500's daily loss of 0.07%.Prior to today's trading, shares of the specialty pharmaceutical company had lost 11.19% over the past month. This has lagged the Medical sector's gain of 7.37% and the S&P 500's gain of 3.98% in that time.Market participants will be closely following the financial results of Amphastar Pharmace ...

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q3 2023 Earnings Conference Call November 8, 2023 5:00 PM ET Company Participants Dan Dischner - SVP of Corporate Communications Bill Peters - CFO Conference Call Participants Glen Santangelo - Jefferies Tim Chiang - Capital One Operator Greetings and welcome to the Amphastar Pharmaceuticals Third Quarter Earnings Conference Call. [Operator Instructions] Please note that certain statements made during this call regarding matters that are not historical facts, in ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (I.R.S. Employer Identification No.) 11570 6 th Street Rancho Cucamonga, CA 91730 (Address of principal executive offices) (zip code) (909) 980-9484 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fro ...

Financial Data and Key Metrics Changes - The company reported revenue of $145.7 million for Q2 2023, an 18% increase from $123.5 million in the same period last year [5][11] - Net income rose to $26.1 million or $0.49 per share, compared to $17.3 million or $0.33 per share in Q2 2022 [17] - Adjusted net income increased by 68% to $34.8 million or $0.65 per share, up from $20.7 million or $0.39 per share in the previous year [17] Business Line Data and Key Metrics Changes - Glucagon injection sales reached $27.3 million, more than doubling from $11.8 million in the prior year, driven by strong market demand [5][11] - Sales of Primatene Mist decreased to $16.5 million from $19 million due to inventory adjustments by retailers, although retail sales grew by 5% [6][12] - Epinephrine sales declined to $16.7 million as competitors returned to normal distribution levels [6][12] - Other finished pharmaceutical products saw a 47% increase in sales, benefiting from competitor shortages [6] Market Data and Key Metrics Changes - The company anticipates a significant role in addressing nationwide drug shortages, particularly in the hospital setting [7] - The FDA approved the brand name Ruxovi for the intranasal naloxone product, with a planned launch delayed to Q4 2023 [7] Company Strategy and Development Direction - The acquisition of BAQSIMI enhances the diabetes portfolio and aligns with the company's focus on proprietary products, biosimilars, and complex products [4] - The company plans to launch glucagon injection in Canada, expanding sales opportunities [14] - Research and development remain a priority, with a focus on advancing the product pipeline and improving margins and cash flow [9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about growth opportunities from new products emerging from the pipeline [10] - The company is in positive dialogue with the FDA regarding AMP-002 and remains hopeful for a successful response [8][35] - Management noted that while there will be an increase in sales from shortage products, it will be incremental due to existing production capacity constraints [30] Other Important Information - Gross margins slightly decreased to 50% from 51% year-over-year, impacted by an impairment charge of $2.7 million related to UK product rights [15] - Selling, distribution, and marketing expenses increased due to higher advertising costs for Primatene Mist [16] Q&A Session Summary Question: Marketing strategy for BAQSIMI and expected sales trends - The transition for BAQSIMI will occur in phases, with the company taking over marketing in Q3, anticipating higher sales during the back-to-school period [20] Question: Sales recovery expectations for Primatene Mist - Sales trends are uncertain, but there is an expectation that the current inventory destocking will eventually stabilize sales [21] Question: Future benefits from ongoing supply shortages - The company expects to continue benefiting from supply shortages, particularly in the hospital market [22][29] Question: Glucagon sales mix and institutional penetration - Approximately 60% of glucagon sales are from retail, with significant growth opportunities in the institutional market [27] Question: Nature of CRL for AMP-008 - The CRL is considered minor, and the company plans to respond in Q3 [28] Question: Impact of Pfizer facility damage on product shortages - The company anticipates some benefits from the damage at the Pfizer facility, particularly in hospital products [30]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2023 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509 | --- | --- | |----------------------------------------------------------------------------------------------------- ...